Canada's Drug Reliance Order: What It Changes for Sponsors

Canada can now lean on the work of trusted foreign regulators when it reviews some new drug submissions. The tool that allows this, the Ministerial Reliance Order, has been in force since July 15, 2026, but its first lists are narrow and its review timelines are unchanged for now ^[1][2]. For most sponsors, the real effect will depend on how fast Health Canada widens those lists and whether it adds incentives.

What the Order actually does

The Order's full name is the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs. It was registered as SOR/2026-162 on July 7, 2026, under section 30.06 of the Food and Drugs Act ^[1]. It took effect on the day it was published in the Canada Gazette, Part II ^[1]. That was July 15, 2026 ^[2].

The key idea is called deeming. When a submission meets the Order's conditions, Health Canada treats its review of certain parts of the file as done, based on a decision or review document from an eligible foreign regulatory authority (FRA) ^[2]. The parts that can be deemed are the clinical, non-clinical, and chemistry and manufacturing information ^[2]. Chemistry and manufacturing is often shortened to CMC.

The Order covers new drugs for human and animal use regulated under Part C, Division 8 of the Food and Drug Regulations ^[1]. It does not apply to public health emergency drugs, extraordinary use new drug submissions, or emergency access routes such as the Special Access Program ^[1]. Health Canada still makes the final decision on whether a drug is authorized in Canada ^[3].

Health Canada framed the Order as a way to cut duplication while keeping Canada's standards for safety, efficacy and quality ^[4]. It also said a faster process should encourage manufacturers to bring products to Canada ^[4].

Why Canada did it now

The government's own analysis is candid about the problem. It says access to some drugs in Canada has lagged, partly because manufacturers make business decisions based on Canada's small share of the global market ^[1]. It also notes that drug submissions keep growing in number and complexity, and that they demand a lot of review effort ^[1].

The Order is tied to the federal Red Tape Review, which began on July 9, 2025 ^[1]. Its stated goals are more timely access, earlier filing in Canada, and freeing up review resources ^[1].

The pressure on reviewers is real in at least one part of the system. In a September 1, 2026 notice, Health Canada said high volumes of more complex generic submissions were straining the review process ^[5]. It said it was "currently not meeting our performance standards for the review of some submissions" ^[5]. In response, it is now reviewing some generic files first, such as those that could help with drug shortages or where no authorized generic exists in Canada ^[5]. That ordering does not change the science or the standard of evidence ^[5].

The same July package also proposed a pilot to move certain generic submissions involving Canadian manufacturing up the queue, citing supply security and shortages ^[4]. Reliance and prioritization are separate tools, but they point the same way: spend scarce review time where Canada adds the most.

Three pathways, one set of conditions

The Order sets out three routes ^[2]:

• General deeming. An eligible FRA has already authorized the foreign drug ^[2].
• 120-day filing. The sponsor files in Canada within 120 days of filing with an eligible FRA, and deeming happens only once that FRA authorizes the drug ^[2].
• Joint review. Health Canada reviews the submission alongside one or more FRAs and relies on parts of their work ^[2].

General deeming is meant for new drug submissions (NDSs), abbreviated new drug submissions (ANDSs) and supplements ^[2]. The 120-day and joint review routes are limited to NDSs and supplements to NDSs ^[2]. They exclude products filed by comparison to an authorized drug, such as generics and biosimilars ^[2].

The conditions are strict. The Canadian drug must match the foreign one in medicinal ingredient, strength, dosage form and route of administration ^[1]. Its conditions of use must fall within those the foreign regulator authorized ^[1]. The sponsor must give the latest approved labels and describe relevant post-market measures ^[1]. It must also disclose any foreign application for the drug that was withdrawn or refused, and explain why that does not affect safety or effectiveness ^[1].

Two more rules matter in practice. The foreign approval generally cannot itself rest on another regulator's reliance decision, unless it came from a joint review ^[2]. And deeming is closed off if an earlier Canadian submission for the drug was withdrawn or cancelled after a deficiency, non-compliance or refusal notice ^[2].

Who is eligible today

Eligibility is set by lists of drug classes and regulators, known as the IbR lists because they are incorporated by reference into the Order ^[1]. There is one list for human drugs and one for veterinary drugs ^[3]. A submission qualifies only if its drug class, submission type and pathway are all expressly listed ^[3].

The human drug list starts small. Health Canada named pediatric drugs and veterinary drugs as the first classes accepted ^[4]. Under general deeming, the human list covers NDSs in a small number of mainly pediatric drug classes, where the submission includes a pediatric indication ^[2]. Supplements in all 14 first-level ATC classes qualify, with exclusions such as vaccines, again only with a pediatric indication ^[2]. ATC is the Anatomical Therapeutic Chemical system for grouping drugs.

Fasken's lawyers gave examples of products on the human list. They include pediatric formulations of anti-epileptic drugs, hydroxyurea products, albendazole products, glucarpidase and bile acid products ^[3].

The eligible regulators for general deeming of human drugs are generally those of Europe, Switzerland, the U.K. and the U.S. ^[2]. Australia is eligible only for albendazole and tuberculosis drugs ^[2]. Joint review is open to NDSs and supplements in all 14 first-level ATC classes, with Australia, Singapore, Switzerland and the U.K. ^[2].

Several things are not on the human list yet. These include general deeming for biosimilars, abbreviated submissions and their supplements, and the 120-day filing route ^[2]. Fasken expects the near-term effect on generic and biosimilar makers to be limited ^[3].

The veterinary list is much broader. NDSs, ANDSs and supplements in all drug classes can use general deeming or 120-day filing ^[2]. Eligible regulators are those of Australia, Europe, New Zealand, the U.K. and the U.S., with only the U.S. FDA eligible for antiparasitic drugs ^[2].

Changes to the lists follow a set rhythm. Updates will typically go through a 75-day consultation and then a six-month wait before they apply ^[2]. New regulators are added only after Health Canada judges their practices comparable to its own ^[2].

How Canada's approach compares

Canada is not first. The U.K. and Australia already run reliance routes, and both tie them to firm review clocks.

The U.K.'s International Recognition Procedure lets applicants use an approval from a reference regulator ^[6]. Its Recognition A route has a 60 calendar day assessment with no clock stop, for reference approvals granted in the past two years ^[6]. Recognition B allows 110 calendar days, plus a clock stop of up to 60 days, for approvals from the past five years ^[6]. The MHRA says both are much shorter than its 150 to 210 day national timetable ^[6]. It still checks things like manufacturing site compliance and pharmacovigilance ^[6].

Australia's comparable overseas regulator route has two versions ^[7]. COR-A has a 120 working day timeframe and needs a full overseas approval no more than one year old ^[7]. COR-B allows 175 working days, permits review of some additional data, and has no age limit on the overseas approval ^[7]. Health Canada is one of the regulators Australia recognizes ^[7].

Canada's design differs in one big way. Health Canada will keep its existing fees and service standards when the Order comes into force ^[1]. Health Canada says it will monitor the effort these reviews take before deciding on further measures ^[1]. Separately, its analysis expects some submissions to have review timelines up to 40% shorter by the end of 2028 ^[1].

Route	Review clock	Age of foreign approval
Canada, general deeming	Existing service standards kept [1]	Foreign authorization must be valid [1]
U.K., Recognition A	60 calendar days, no clock stop [6]	Within 2 years [6]
U.K., Recognition B	110 calendar days plus clock stop [6]	Within 5 years [6]
Australia, COR-A	120 working days [7]	No more than 1 year old [7]
Australia, COR-B	175 working days [7]	No age limit [7]

What the evidence shows

Health Canada did not start from a slow base. It says it meets its service standard for Division 8 drugs more than 95% of the time, and has for five years ^[1]. Its median review time for priority submissions in 2024 was 223 days, which it says ranks first among comparable regulators ^[1]. So reliance is less about speeding up a slow review and more about getting files into Canada earlier.

The cost numbers are modest. The government estimates that deeming will save industry about $27,675 per submission, mostly through about 1.5 fewer information requests ^[1]. Showing eligibility is expected to cost about $9,600, for a net saving of $18,075 per submission ^[1]. It could not estimate the number of eligible submissions with confidence, and gave a floor of 19 a year ^[1].

Support was broad but not universal. The prepublished Order drew comments from 120 stakeholders during a consultation that ran from December 20, 2025, to March 14, 2026 ^[1]. Most supported it, and some urged more caution ^[1]. Concerns included a loss of Health Canada expertise, approvals with no intent to sell in Canada, and knock-on effects on health technology assessment and reimbursement ^[1]. Health Canada's answer was that review resources would be refocused, not reduced ^[1].

There is not much hard evidence yet that reliance brings more useful drugs to market. Joel Lexchin, a University of Toronto associate professor, cites an Australian study, now under peer review, of 29 drugs that used that country's reliance route ^[8]. Of 22 assessed by health technology bodies, 16 offered only minor therapeutic gains and 2 offered a major benefit ^[8]. He also points to a study of 42 cancer drugs approved between 1995 and 2008, which found FDA and European decisions differed in almost 50 per cent of cases ^[8].

The open questions

Industry groups want the Order to go further and faster. BIOTECanada wants the lists expanded to oncology, HIV, antimicrobial drugs, vaccines and rare disease drugs ^[9]. It questions the six-month delay before list changes apply and suggests 30 to 60 days instead ^[9]. It also wants a 60-day standard for telling sponsors whether deeming is accepted, and shorter review timelines for deemed files ^[9].

BIOTECanada also flagged draft wording that would bar deeming when safety-related changes are still under foreign review, which it says "will significantly hamper" the Order's implementation ^[9]. It asked for earlier eligibility checks, pointing to the MHRA's tracker as a model ^[9].

Critics worry about the opposite risk. Lexchin argues that Canada could have approved a drug like aducanumab under a reliance system ^[8]. An FDA advisory committee had voted 10 of 11 against that Alzheimer's drug, with the 11th member abstaining ^[8]. His point is that foreign decisions are not uniform, and that reliance imports their weaknesses along with their strengths ^[8].

Pricing may matter more than review speed. Fasken's lawyers conclude that the Order's effect is significantly reduced by the rules of the Patented Medicine Prices Review Board (PMPRB) and the U.S. Most Favoured Nation pricing policy ^[3]. Health Canada's own analysis notes that authorization is only one step, and that provincial reimbursement and health technology assessment also shape access ^[1].

Intellectual property rules do not change. The Order does not affect data protection, the Patented Medicines (Notice of Compliance) Regulations, or certificates of supplementary protection ^[2].

What it means for people in the industry

Regulatory affairs. Teams filing pediatric indications in Canada should check the IbR lists now. Deeming must be requested at filing, with proof that the Canadian product matches the foreign one ^[3]. A sponsor's request and attestation form is part of the package ^[2]. Global teams should also plan Canadian filings closer to major foreign filings, since Fasken expects the 120-day route to encourage that once it opens for human drugs ^[3].

Clinical and CMC. Any difference from the foreign product, in formulation, site or labelling, must be disclosed and shown not to affect safety or effectiveness ^[1]. Health Canada reviews those differences itself ^[1]. Keeping Canadian and foreign dossiers aligned becomes a practical advantage.

Quality and pharmacovigilance. Sponsors must describe relevant post-market measures and disclose foreign withdrawals or refusals ^[1]. Health Canada can also ask for more information ^[1]. Clean, well-linked global records will matter.

Generics and biosimilars. For now, reliance offers these firms little ^[3]. The more relevant change is Health Canada's review prioritization for some generic files ^[5]. Firms with Canadian manufacturing should watch the proposed domestic pilot ^[4].

Business development and market access. Reliance lowers one barrier, but pricing and reimbursement still decide whether a launch makes sense ^[3]. Bettina Hamelin, president and CEO of Innovative Medicines Canada, warned that Canada's appeal as a launch market is under pressure ^[4]. Teams weighing a Canadian launch should model both the regulatory saving and the pricing outlook.

For more coverage of approvals and policy, see PharmoniQ news.

Key takeaways

• Canada's Ministerial Reliance Order has been in force since July 15, 2026, and lets Health Canada deem parts of a review complete based on trusted foreign regulators ^[2].
• There are three routes: general deeming, 120-day filing and joint review, each with strict sameness conditions ^[1][2].
• The first human drug list is narrow and mostly pediatric, while the veterinary list covers all classes ^[2].
• Unlike the U.K. and Australia, Canada set no dedicated faster clock for reliance files at launch, keeping its existing service standards and fees ^[1][6][7].
• The estimated saving is about $18,075 per eligible submission, with at least 19 such submissions a year ^[1].
• Industry wants wider lists and faster timelines, while critics question whether reliance brings more valuable drugs ^[9][8].
• Pricing and reimbursement may limit the Order's effect more than any review rule ^[3].

References

1. Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs: SOR/2026-162. Canada Gazette, Part II, Jul 15, 2026.
2. Ministerial Reliance Order permitting Health Canada to rely on decisions of foreign regulators now in force. Smart & Biggar, Jul 31, 2026.
3. Health Canada's New Draft Guidance on Foreign Regulatory Reliance for Certain Drugs. Fasken, Jul 17, 2026.
4. Helping Canadians access safe, effective treatments and medicines faster. Health Canada, Jul 15, 2026.
5. Health Canada takes action to prioritize generic drug submissions: Notice. Health Canada, Sep 1, 2026.
6. International Recognition Procedure: supplementary information. Medicines and Healthcare products Regulatory Agency (GOV.UK), Oct 9, 2026.
7. TGA looks to comparable overseas regulators to speed up access to new medicines. PharmaLex.
8. Why drug approval in Canada should not rely on foreign regulators. Social Policy in Ontario (republished from The Conversation), Jan 30, 2026.
9. Reliance order comments. BIOTECanada, Sep 10, 2026.